New Risk • Jun 03
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$447k). Minor Risk Market cap is less than US$100m (€28.0m market cap, or US$32.4m). New Risk • Dec 31
New major risk - Revenue and earnings growth Revenue has declined by 41% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Negative equity (-€656k). Revenue has declined by 41% over the past year. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.1m). New Risk • Dec 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$451k). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (€24.8m market cap, or US$29.0m). New Risk • Oct 03
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€656k). Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (€385k revenue, or US$452k). Minor Risk Market cap is less than US$100m (€31.8m market cap, or US$37.3m). New Risk • Jun 18
New major risk - Negative shareholders equity The company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.55m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m). 공시 • May 10
Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025 Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France 